Nora Liebers

TL;DR: CAR T-cell outcomes were not inferior to alloHCT outcomes, whether measured by ITT or from CI administration, supporting strategies preferring CAR T cells over allo HCT as first CI for multiply R/R LBCL.

TL;DR: The modified immunoRNase exhibited exceptionally high cytotoxicity toward EGFR-expressing head and neck cell lines without affecting specificity, indicating that endosomal entrapment needs to be considered for Ranpirnase-based immunoagents and might be overcome by the use of tailored transduction domains from viral proteins.

TL;DR: It is suggested that by targeted delivery of Ranpirnase non-selective toxicity can be abolished and suggests Ran Pirnase-diabody as a promising new drug for therapeutic interventions in EGFR-positive cancers.

TL;DR: In this paper , the relevance of proteomics for disease classifications remains to be established in clinically heterogeneous cancer entities such as chronic lymphocytic leukemia (CLL), where the authors characterize the proteome and transcriptome alongside genetic and ex-vivo drug response profiling in a clinically annotated CLL discovery cohort.